Soovu Wearable Pain Relief – A “Therable” for Chronic Pain Relief

Soovu ™ Wearable Pain Relief, is a unique “therable” (wearable medical device and app) to treat chronic pain.

In the U.S. more money is spent on pain treatments and lost productivity than diabetes, cancer and heart disease combined. Clearly opioids are not the answer, and recently the FDA required NSAIDs, like Aleve and Advil, to include heart attack and stroke warnings on their labels. According to Chuck Chabal, MD and Co-Founder of Soovu Labs, “In the COVID era, pain complaints are up by 50%, as are comorbidities of anxiety, stress and depression. The need for transformation in the management of pain has never been greater.”

With funding from the National Institutes of Health, Dr. Chabal and fellow researcher and Co-Founder Dr. Peter Dunbar developed a drug-free, wearable for on-the-go relief.  These doctors discovered that pulsing high levels of heat on the skin desensitized the “TRPV1” receptor, and in so doing provided immediate and long-lasting relief of chronic pain1. Published, independent clinical studies confirmed that Soovu significantly reduced chronic pain compared to a placebo device. The Soovu companion app provides digital coaching to reduce stress and anxiety associated with pain, and sends results to the cloud for machine learning for personalized treatments. The device and app uniquely address both physiological and psychological pathways to pain relief.

Soovu Labs is currently completing a round of funding to scale up production. With its launch of Soovu Wearable Pain Relief in fall 2021, the company is poised to reduce the pain of millions of Americans and increase the possibilities in their lives.

Soovu Labs, Inc. is on a mission to transform the treatment of chronic pain without drugs, invasive procedures or surgery.  Their first product, Soovu Wearable Pain Relief, will target treatment of chronic back and neck pain.


Soovu Wearable Pain Therapy is indicated to provide topical heating for the purpose of elevating tissue temperature for the temporary relief of minor muscle and joint pain and stiffness; the temporary relief of joint pain associated with arthritis; the temporary relief of muscle spasms, minor sprains and strains, and minor muscular back pain; the temporary relief of menstrual discomfort; the relaxation of muscles; and the temporary increase of local circulation where applied.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version